Cytokinetics, Incorporated · South San Francisco, CA United States (NASDAQ: CYTK)
| 280 E. Grand Ave. | Phone: 650-624-3000 |
| South San Francisco, CA | Fax: 650-624-3010 |
| 94080 | |
| United States | 
Map This Company |
Cytokinetics, Incorporated Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Cytokinetics studies the cytoskeleton to get to the heart of the problem. The biopharmaceutical firm's drug development technologies aim to treat disease by modulating muscle function through manipulation of the cytoskeleton (biological infrastructure of cells). Its pipeline includes lead candidate omecamtiv mecarbil, which is designed for the treatment of heart failure based on a cytoskeletal protein in the heart muscle. It is being developed in collaboration with
Cytokinetics, Incorporated Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: CYTK Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 105 |
Executives
25 executives listed for Cytokinetics, Incorporated's South San Francisco, CA location.
| Chairman | L. Patrick Gage | |
|---|---|---|
| Principal | Mary Rogers | |
| President, CEO, and Director | Robert Blum |